| Date | Title | Description |
| 31.10.2024 | ODI Pharma AB: A New Chapter on the Horizon | In the world of pharmaceuticals, change is the only constant. ODI Pharma AB, a player in the medical cannabis market, is gearing up for a significant transformation. On November 19, 2024, the company will hold an Extraordinary General Meeti... |
| 30.10.2024 | ODI Pharma AB decides on a preferential issue of shares and to bring forward publication of the Q1-report | ODI Pharma AB decides on a preferential issue of shares and to bring forward publication of the Q1-report
Wed, Oct 30, 2024 15:40 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNI... |
| 30.10.2024 | Notice of Extraordinary General Meeting in ODI Pharma AB (publ) | Notice of Extraordinary General Meeting in ODI Pharma AB (publ)
Wed, Oct 30, 2024 15:42 CET Report this content
The shareholders of ODI Pharma AB (publ), 559223-1392, are hereby invited to an Extraordinary General Meeting to be held on Tues... |
| 30.10.2024 | Proposal for change in the Board of Directors of ODI Pharma AB | Proposal for change in the Board of Directors of ODI Pharma AB
Wed, Oct 30, 2024 15:41 CET Report this content
Malcolm Allan is proposed to be elected as a new member of the Board of Directors of ODI Pharma AB at the Extraordinary General M... |
| 25.06.2024 | ODI Pharma AB announces strategic market entry with initial shipment to Switzerland | ODI Pharma AB announces strategic market entry with initial shipment to Switzerland
Tue, Jun 25, 2024 18:35 CET Report this content
ODI Pharma AB (“ODI” or the “Company”) is pleased to announce the first delivery of cannabis products to the... |
| 30.05.2024 | ODI Pharma AB: Publication of interim report Q3 2023/2024 | ODI Pharma AB: Publication of interim report Q3 2023/2024
Thu, May 30, 2024 11:45 CET Report this content
ODI Pharma AB (“ODI” or the “Company”) hereby publishes its interim report for the period July 2023 - March 2024. The report is availa... |
| 02.05.2024 | Preliminary results for ODI Pharma indicate significant revenue increase in Q3 2023/2024 | Preliminary results for ODI Pharma indicate significant revenue increase in Q3 2023/2024
Thu, May 02, 2024 13:30 CET Report this content
ODI Pharma AB (“ODI” or the “Company”) announces today that the preliminary financial results for the t... |
| 27.02.2024 | ODI Pharma AB: Updated market and business overview | ODI Pharma AB: Updated market and business overview
Tue, Feb 27, 2024 17:00 CET Report this content
ODI Pharma AB (“ODI” or the “Company”) hereby present an updated overview of its market position and the latest trends observed in the canna... |
| 18.01.2024 | ODI Pharma AB appoints Pareto Securities AB as liquidity provider | ODI Pharma AB appoints Pareto Securities AB as liquidity provider
Thu, Jan 18, 2024 18:00 CET Report this content
ODI Pharma AB (“ODI Pharma” or the “Company”) has today appointed Pareto Securities as the liquidity guarantor for the Company... |
| 15.12.2023 | Announcement from the Annual General Meeting in ODI Pharma AB (publ) | Announcement from the Annual General Meeting in ODI Pharma AB (publ)
Fri, Dec 15, 2023 11:15 CET Report this content
This is an unofficial translation of a notice to the Annual General Meeting in ODI Pharma AB (publ), originally drafted in ... |
| 06.12.2023 | ODI Pharma AB announces sale of the skincare brand kandol. for 3.2 msek | ODI Pharma AB announces sale of the skincare brand kandol. for 3.2 msek
Wed, Dec 06, 2023 13:53 CET Report this content
ODI Pharma AB (“ODI” or the “Company”) announces today the sale of the skincare brand kandol. to Niclas Kappelin. The tr... |
| 29.11.2023 | Medicinal Cannabis Startup Cannarma Raises Funding To Diversify Product Line The capital was raised from Zero to One Fund at pre-money Valuation of $2.04 million | - |
| 27.11.2023 | Correction: ODI Pharma AB publishes the annual report for the fiscal year 2022/2023 | Correction: ODI Pharma AB publishes the annual report for the fiscal year 2022/2023
Mon, Nov 27, 2023 13:17 CET Report this content
The correction refers to the completion of the auditor's remark and ODI Pharma's comment which is now includ... |
| 24.11.2023 | ODI Pharma AB: Publication of interim report report Q1 2023/2024 | ODI Pharma AB: Publication of interim report report Q1 2023/2024
Fri, Nov 24, 2023 17:45 CET Report this content
ODI Pharma AB (“ODI” or the “Company”) hereby publishes its interim report for the period July 2023 – September 2023. The repor... |
| 24.11.2023 | ODI Pharma AB publishes the annual report for the fiscal year 2022/2023 | ODI Pharma AB publishes the annual report for the fiscal year 2022/2023
Fri, Nov 24, 2023 17:45 CET Report this content
The Board of Directors and the Chief Executive Officer of ODI Pharma AB (“ODI Pharma”) hereby publishes the annual repor... |
| 23.11.2023 | ODI Pharma AB postpones publication of interim report and annual report until November 24, 2023 | ODI Pharma AB postpones publication of interim report and annual report until November 24, 2023
Thu, Nov 23, 2023 19:45 CET Report this content
ODI Pharma AB (“ODI” or the “Company”) stated in its year-end report that the interim report for... |
| 13.11.2023 | Notice to Annual General Meeting in ODI Pharma AB (publ) | Notice to Annual General Meeting in ODI Pharma AB (publ)
Mon, Nov 13, 2023 14:35 CET Report this content
The shareholders of ODI Pharma AB (publ), 559223–1392, are hereby invited to attend the Annual General Meeting on Friday, 15th of Decem... |
| 24.08.2023 | ODI Pharma AB: Publication of year-end report for the fiscal year 2022/2023 | ODI Pharma AB: Publication of year-end report for the fiscal year 2022/2023
Thu, Aug 24, 2023 19:00 CET Report this content
ODI Pharma AB (“ODI” or the “Company”) hereby publishes its year-end report for the period July 2022 – June 2023. Th... |
| 05.06.2023 | Budding medicinal cannabis startup bags £1m seed round | Investors have high expectations for a medicinal cannabis startup based on the Isle of Man, which has secured a £1m seed funding round.
Grow Lab Organics – founded by Alex Fray, Charlie Price, and Charlie Lyons – is researching and growing ... |
| 25.05.2023 | ODI Pharma AB: Publication of interim report report Q3 2022/2023 | ODI Pharma AB: Publication of interim report report Q3 2022/2023
Thu, May 25, 2023 18:06 CET Report this content
ODI Pharma AB (“ODI” or the “Company”) hereby publishes its interim report for the period July 2022 – March 2023. The report is... |
| 23.02.2023 | ODI Pharma AB: Publication of half-year report 2022/2023 | ODI Pharma AB: Publication of half-year report 2022/2023
Thu, Feb 23, 2023 17:47 CET Report this content
ODI Pharma AB (“ODI” or the “Company”) hereby publishes its half-year report for the period July – December 2022. The report is availab... |
| 24.01.2023 | ODI Pharma receives approval from the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in Poland to distribute and sell its products on the Polish market | ODI Pharma receives approval from the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in Poland to distribute and sell its products on the Polish market
Tue, Jan 24, 2023 13:57 CET Report this content
OD... |
| 16.12.2022 | Announcement from the Annual General Meeting in ODI Pharma AB (publ) | Announcement from the Annual General Meeting in ODI Pharma AB (publ)
Fri, Dec 16, 2022 11:22 CET Report this content
This is an unofficial translation of a notice to the Annual General Meeting in ODI Pharma AB (publ), originally drafted in ... |
| 25.11.2022 | ODI Pharma AB publishes the annual report for the fiscal year 2021/2022 | ODI Pharma AB publishes the annual report for the fiscal year 2021/2022
Fri, Nov 25, 2022 19:50 CET Report this content
The Board of Directors and the Chief Executive Officer of ODI Pharma AB (“ODI Pharma”) hereby publishes the annual repor... |
| 24.11.2022 | ODI Pharma AB postpones publication of interim report and annual report until November 25, 2022 | ODI Pharma AB postpones publication of interim report and annual report until November 25, 2022
Thu, Nov 24, 2022 19:30 CET Report this content
ODI Pharma AB (“ODI” or the “Company”) stated in its year-end report that the interim report for... |
| 25.08.2022 | ODI Pharma AB: Publication of year-end report for the fiscal year 2021/2022 | ODI Pharma AB: Publication of year-end report for the fiscal year 2021/2022
Thu, Aug 25, 2022 19:00 CET Report this content
ODI Pharma AB (“ODI” or the “Company”) hereby publishes its year-end report for the period July 2021 – June 2022. Th... |
| 25.02.2022 | Correction: ODI Pharma AB: Publication of half-year report 2021 | Correction: ODI Pharma AB: Publication of half-year report 2021
Fri, Feb 25, 2022 21:33 CET Report this content
Correction: ODI Pharma hereby discloses a revised half-year report for the period July – December 2021. In the previous report, ... |
| 24.02.2022 | ODI Pharma AB: Publication of half-year report 2021 | ODI Pharma AB: Publication of half-year report 2021
Thu, Feb 24, 2022 19:47 CET Report this content
ODI Pharma AB (“ODI” or the “Company”) hereby publishes its half-year report for the period July – December 2021. The report is available as... |
| - | ODI Pharma | “ODI Pharma AB, based on it's European network, subsidiaries and affiliates, is a producer of pharmaceutical cannabis products with a focus on distribution to medicinal markets in Europe. The main focus of ODI Pharma....” |
